[{"id":"25020878-ebf8-4c6a-b993-cf53eea8f872","acronym":"USZ-STRIKE","url":"https://clinicaltrials.gov/study/NCT05522660","created_at":"2022-08-31T15:56:47.406Z","updated_at":"2024-07-02T16:35:06.364Z","phase":"Phase 3","brief_title":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05522660 - USZ-STRIKE","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-02"},{"id":"4778a574-5f01-405a-9873-c9cc5d26ae19","acronym":"","url":"https://clinicaltrials.gov/study/NCT03903705","created_at":"2021-01-18T19:12:53.641Z","updated_at":"2024-07-02T16:35:07.454Z","phase":"Phase 1/2","brief_title":": A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors","source_id_and_acronym":"NCT03903705","lead_sponsor":"Hutchmed","biomarkers":" PD-L1 • ALK • ROS1 • IFNA1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion","tags":["PD-L1 • ALK • ROS1 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 381","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-25"},{"id":"f2b35136-f790-410c-b54a-4f61af16101b","acronym":"ZWI-ZW25-101","url":"https://clinicaltrials.gov/study/NCT02892123","created_at":"2021-01-17T17:13:28.525Z","updated_at":"2024-07-02T16:35:08.789Z","phase":"Phase 1","brief_title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","source_id_and_acronym":"NCT02892123 - ZWI-ZW25-101","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" EGFR • HER-2 • KRAS • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion","tags":["EGFR • HER-2 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-18"},{"id":"e3283371-d5d3-4a68-bf39-709bf00315cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05701787","created_at":"2023-01-27T16:00:02.113Z","updated_at":"2024-07-02T16:35:09.119Z","phase":"","brief_title":"Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations","source_id_and_acronym":"NCT05701787","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR • KRAS • BRAF • ALK • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • ALK fusion • ROS1 fusion • KRAS G12 • ALK-ROS1 fusion • NTRK fusion","tags":["EGFR • KRAS • BRAF • ALK • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • ALK fusion • ROS1 fusion • KRAS G12 • ALK-ROS1 fusion • NTRK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-04-17"},{"id":"01c9490b-851c-40e3-bd81-bb560b20b9de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777084","created_at":"2021-03-02T12:52:16.287Z","updated_at":"2024-07-02T16:35:25.092Z","phase":"Phase 1","brief_title":"The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.","source_id_and_acronym":"NCT04777084","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • reozalimab (IBI318)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-12-27"},{"id":"03b258b9-b6b1-4be5-9722-9374ceff289d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03917043","created_at":"2021-09-06T03:53:55.845Z","updated_at":"2024-07-02T16:35:28.475Z","phase":"Phase 1","brief_title":"APG-2449 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03917043","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APG-2449"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-11-21"},{"id":"84ae37b2-6f5c-4e7e-be94-a941521ec5e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05863325","created_at":"2023-05-18T14:04:44.124Z","updated_at":"2024-07-02T16:35:30.313Z","phase":"Phase 2","brief_title":"A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05863325","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • albumin-bound docetaxel (CPO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/27/2023","start_date":" 06/27/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-06"},{"id":"05757d5b-0f8e-42a9-aeba-53209e538f06","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638425","created_at":"2022-12-06T16:58:33.394Z","updated_at":"2024-07-02T16:35:59.621Z","phase":"","brief_title":"Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases","source_id_and_acronym":"NCT05638425","lead_sponsor":"Xiangya Hospital of Central South University","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-12-06"},{"id":"54a08916-fdc5-4698-a668-516e88739181","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273814","created_at":"2022-03-10T13:52:40.973Z","updated_at":"2024-07-02T16:36:07.391Z","phase":"Phase 1","brief_title":"Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer","source_id_and_acronym":"NCT05273814","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2022-07-13"},{"id":"2e44d71c-ed7e-4837-a244-9d339efa5e0f","acronym":"VinMetAtezo","url":"https://clinicaltrials.gov/study/NCT03801304","created_at":"2021-01-18T18:47:28.807Z","updated_at":"2024-07-02T16:36:10.519Z","phase":"Phase 2","brief_title":"Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03801304 - VinMetAtezo","lead_sponsor":"University Hospital, Brest","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • vinorelbine tartrate"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 01/04/2021","primary_completion_date":" 01/04/2021","study_txt":" Completion: 02/23/2022","study_completion_date":" 02/23/2022","last_update_posted":"2022-05-12"},{"id":"6d57522c-e167-43b0-91dd-c86a02aeca40","acronym":"","url":"https://clinicaltrials.gov/study/NCT05346952","created_at":"2022-04-26T13:53:49.954Z","updated_at":"2024-07-02T16:36:11.496Z","phase":"Phase 3","brief_title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","source_id_and_acronym":"NCT05346952","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • pemetrexed • Andewei (benmelstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 01/25/2022","start_date":" 01/25/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-26"},{"id":"18228bfe-0dc7-4331-ad1d-d0bebdb05d54","acronym":"","url":"https://clinicaltrials.gov/study/NCT01449461","created_at":"2021-01-17T17:28:43.410Z","updated_at":"2024-07-02T16:36:26.255Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)","source_id_and_acronym":"NCT01449461","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement • ROS1 fusion • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 09/20/2011","start_date":" 09/20/2011","primary_txt":" Primary completion: 11/16/2015","primary_completion_date":" 11/16/2015","study_txt":" Completion: 02/18/2020","study_completion_date":" 02/18/2020","last_update_posted":"2021-08-17"},{"id":"1b98a4a8-2e46-444b-81a2-fb56f00d1be6","acronym":"ONCOPRO","url":"https://clinicaltrials.gov/study/NCT03787056","created_at":"2021-01-18T18:43:26.337Z","updated_at":"2024-07-02T16:36:27.812Z","phase":"","brief_title":"Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients","source_id_and_acronym":"NCT03787056 - ONCOPRO","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" MUC16","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 12/04/2018","start_date":" 12/04/2018","primary_txt":" Primary completion: 01/04/2028","primary_completion_date":" 01/04/2028","study_txt":" Completion: 01/04/2028","study_completion_date":" 01/04/2028","last_update_posted":"2021-07-16"},{"id":"2ca1ff45-c374-4801-b9ec-433565778ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04675060","created_at":"2021-01-19T20:45:37.210Z","updated_at":"2024-07-02T16:36:32.534Z","phase":"Phase 1","brief_title":"Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules","source_id_and_acronym":"NCT04675060","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ALK • MET • ROS1","pipe":" | ","alterations":" MET amplification • ALK fusion • ALK mutation • ROS1 fusion • MET mutation • ALK-ROS1 fusion","tags":["ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • ALK fusion • ALK mutation • ROS1 fusion • MET mutation • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anluoqing (envonalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/23/2021","start_date":" 02/23/2021","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2021-04-01"},{"id":"636ea5e9-1110-4fcd-8e8e-f4c941183660","acronym":"","url":"https://clinicaltrials.gov/study/NCT04459663","created_at":"2021-01-18T21:26:38.040Z","updated_at":"2024-07-02T16:36:43.532Z","phase":"Phase 2","brief_title":"JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.","source_id_and_acronym":"NCT04459663","lead_sponsor":"Li Zhang, MD","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • axitinib"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-07-07"}]